EQNR vs GFR

Equinor exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is currently trading at a severe premium to its deterministic value. The current price of $37.94 is more than double the Graham Number ($18.78) and nearly triple the growth-based intrinsic value ($13.58). This valuation gap is compounded by sharply negative growth metrics, including a 27.3% YoY decline in earnings and a 0/100 bearish technical trend. While the balance sheet is healthier than the sector average, the combination of valuation overshoot and deteriorating fundamentals suggests significant downside risk.

GFR presents a stark dichotomy between a fortress balance sheet and collapsing operational performance. While the Piotroski F-Score of 4/9 indicates stable but mediocre financial health, the company's near-zero debt (Debt/Equity 0.01) and P/B ratio of 0.92 provide a significant valuation floor. However, catastrophic revenue declines (-35.4% YoY) and a string of earnings misses (0/4 beats) suggest a severe deterioration in core business momentum. The stock is defensively undervalued per the Graham Number ($8.55) but fundamentally overpriced relative to its growth-based intrinsic value ($3.36).